 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Beta-Blockers Improve Survival and Decrease Hospitalizations in Patients with Heart Failure
3 April 2001 | Volume 134 Issue 7 | Page S94
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "ß-Blockers in Congestive Heart Failure. A Bayesian Meta-Analysis." It is in the 3 April 2001 issue of Annals of Internal Medicine (volume 134, pages 550-560). The authors are JM Brophy, L Joseph, and JL Rouleau.
What is the problem and what is known about it so far?
Congestive heart failure is a condition in which the heart muscle cannot pump blood normally, leading to such symptoms as shortness of breath and fluid accumulation. Heart failure is a common and serious illness in the United States, particularly in older adults. Although many medicines improve symptoms and survival in heart failure, patients with this condition often do not do well, and better treatments are needed. ß-Blockers are drugs that slow the heart rate, lower blood pressure, decrease the strength of heart muscle contraction, and prevent abnormal heart rhythms. Some studies have suggested that ß-blockers may help patients with heart failure, but the likelihood that they are helpful is unclear.
Why did the researchers do this particular study?
To find out whether ß-blockers decrease hospitalization and improve survival in adults with heart failure.
Who was studied?
The researchers studied 10,136 patients with heart failure who had participated in previous studies of the use of ß-blockers in heart failure. Patients mostly had mild or moderately severe heart failure; most were already receiving three other drugs for heart failure (digitalis, diuretics, and angiotensin-converting enzyme inhibitors).
How was the study done?
Rather than doing a new study, the researchers analyzed information from 22 previous studies that had assigned patients with heart failure to receive ß-blockers or placebo. Placebos were tablets that looked like ß-blockers but contained no active ingredient. Individual studies compared two types of ß-blockers to placebo; one type has specific effects on the heart (cardioselective agents), and one affects other organs as well as the heart (nonselective agents). Certain other types of ß-blockers were avoided because they may actually increase mortality.
What did the researchers find?
Compared with patients taking placebo, patients taking ß-blockers were hospitalized less often and died less often of heart failure. The authors estimated that ß-blockers saved 3.8 lives and prevented 4 hospitalizations for every 100 patients who were treated for 5 years.
What were the limitations of the study?
The patients in these studies were specially selected. Moreover, many study patients received test doses of ß-blockers and did not participate further if they had adverse effects with test doses. Doses of ß-blockers were increased very slowly, and patients were followed very closely. The adverse effects of ß-blockers may be more common in everyday life than they were in these carefully controlled studies.
What are the implications of the study?
ß-Blockers reduce hospitalizations and deaths in patients who are already receiving other therapies for heart failure. These drugs must be given carefully and advanced slowly to moderately high doses.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  G. C. Fonarow, W. T. Abraham, N. M. Albert, W. G. Stough, M. Gheorghiade, B. H. Greenberg, C. M. O'Connor, J. L. Sun, C. W. Yancy, J. B. Young, et al. Influence of Beta-Blocker Continuation or Withdrawal on Outcomes in Patients Hospitalized With Heart Failure Findings From the OPTIMIZE-HF Program. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 190 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S G. Carruthers Reminders in echocardiography reports increased use of blockers in reduced left ventricular ejection fraction Evid. Based Med., December 1, 2007; 12(6): 185 - 185. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Leibovici, A. Gafter-Gvili, M. Paul, N. Almanasreh, E. Tacconelli, S. Andreassen, A.D. Nielsen, U. Frank, R. Cauda, and for the TREAT Study Group Relative tachycardia in patients with sepsis: an independent risk factor for mortality QJM, October 1, 2007; 100(10): 629 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Bracken, E. Mannucci, M. Monami, N. Marchionni, G. A. Diamond, S. Kaul, A. S. Brett, S. E. Nissen, K. Wolski, B. M. Psaty, et al. Rosiglitazone and Cardiovascular Risk N. Engl. J. Med., August 30, 2007; 357(9): 937 - 940. [Full Text] [PDF]
|
|
|
|
|
|
S. Bangalore, F. H. Messerli, J. B. Kostis, and C. J. Pepine Cardiovascular Protection Using Beta-Blockers: A Critical Review of the Evidence J. Am. Coll. Cardiol., August 14, 2007; 50(7): 563 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Chugh, K. Reinier, and E. C. Stecker Learning From a Real-World Analysis of Implantable Cardioverter-Defibrillator Recipients: Comorbidities Matter J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2416 - 2418. [Full Text] [PDF]
|
|
|
|
 |
|
 E. B Friedrich and M. Bohm MANAGEMENT OF END STAGE HEART FAILURE Heart, May 1, 2007; 93(5): 626 - 631. [Full Text] [PDF]
|
|
|
|
|
|
M. Rivero-Ayerza, D. A.M.J. Theuns, H. M. Garcia-Garcia, E. Boersma, M. Simoons, and L. J. Jordaens Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials Eur. Heart J., November 2, 2006; 27(22): 2682 - 2688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bourque, C. M. O'Connor, and E. J. Velazquez Letter by Bourque et al Regarding Article, "Changing Incidence and Survival for Heart Failure in a Well-Defined Older Population, 1970-1974 and 1990-1994" Circulation, August 15, 2006; 114(7): e255 - e255. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Khan and F. A. McAlister Re-examining the efficacy of {beta}-blockers for the treatment of hypertension: a meta-analysis Can. Med. Assoc. J., June 6, 2006; 174(12): 1737 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Ko, J. V. Tu, F. A. Masoudi, Y. Wang, E. P. Havranek, S. S. Rathore, A. M. Newman, L. R. Donovan, D. S. Lee, J. M. Foody, et al. Quality of Care and Outcomes of Older Patients With Heart Failure Hospitalized in the United States and Canada Arch Intern Med, November 28, 2005; 165(21): 2486 - 2492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Singh {beta}-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S3 - S14. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy, and A. Laupacis Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure JAMA, September 14, 2005; 294(10): 1240 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. A. Ioannidis Contradicted and Initially Stronger Effects in Highly Cited Clinical Research JAMA, July 13, 2005; 294(2): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ducharme, O. Doyon, M. White, J. L. Rouleau, and J. M. Brophy Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial Can. Med. Assoc. J., July 5, 2005; 173(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Weiner, T E Stump, C M Callahan, J N Lewis, and C J McDonald Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications Qual. Saf. Health Care, April 1, 2005; 14(2): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nanthakumar, A. E. Epstein, G. N. Kay, V. J. Plumb, and D. S. Lee Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2166 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ezekowitz, F. A. McAlister, K. H. Humphries, C. M. Norris, M. Tonelli, W. A. Ghali, M. L. Knudtson, and APPROACH Investigators The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1587 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister, J. A. Ezekowitz, N. Wiebe, B. Rowe, C. Spooner, E. Crumley, L. Hartling, T. Klassen, and W. Abraham Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure Ann Intern Med, September 7, 2004; 141(5): 381 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Gluckman, B. Baranowski, M. D. Ashen, C. A. Henrikson, M. McAllister, J. B. Braunstein, and R. S. Blumenthal A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction Arch Intern Med, July 26, 2004; 164(14): 1490 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chatterjee The Fear of {beta}-Blocker Therapy in Heart Failure: Time to Forget Arch Intern Med, July 12, 2004; 164(13): 1370 - 1371. [Full Text] [PDF]
|
|
|
|
|
|
D. T. Ko, P. R. Hebert, C. S. Coffey, J. P. Curtis, J. M. Foody, A. Sedrakyan, and H. M. Krumholz Adverse Effects of {beta}-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials Arch Intern Med, July 12, 2004; 164(13): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P McElduff, G Lyratzopoulos, R Edwards, R F Heller, P Shekelle, and M Roland Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK Qual. Saf. Health Care, June 1, 2004; 13(3): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Kernis, K. J. Harjai, G. W. Stone, L. L. Grines, J. A. Boura, W. W. O'Neill, and C. L. Grines Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1773 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma Ann Intern Med, May 18, 2004; 140(10): 802 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Thornton and A. Ahmed Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1333 - 1333. [Full Text] [PDF]
|
|
|
|
|
|
M. G. Shlipak Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency Ann Intern Med, June 3, 2003; 138(11): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Brophy, P. Belisle, and L. Joseph Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis Ann Intern Med, May 20, 2003; 138(10): 777 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Reed, P. W. Dillingham, A. H. Briggs, D. L. Veenstra, and S. D. Sullivan A Bayesian Approach to Aid in Formulary Decision Making: Incorporating Institution-Specific Cost-Effectiveness Data with Clinical Trial Results Med Decis Making, May 1, 2003; 23(3): 252 - 264. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Soler-Soler and D. Garcia-Dorado How to best to counteract the enemies? By blocking neurohormonal activation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G45 - G50. [Abstract] [PDF]
|
|
|
|
|
|
Y. Wu, J. Temple, R. Zhang, I. Dzhura, W. Zhang, R. Trimble, D. M. Roden, R. Passier, E. N. Olson, R. J. Colbran, et al. Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy Circulation, September 3, 2002; 106(10): 1288 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Philipp, M. Brede, and L. Hein Physiological significance of alpha 2-adrenergic receptor subtype diversity: one receptor is not enough Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R287 - R295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. McCafferty, D. Sorbellini, and P. Cianci Telemetry to Home: Successful Discharge of Patients With Ventricular Assist Devices Crit. Care Nurse, June 1, 2002; 22(3): 43 - 51. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Merlet, L. Hittinger, J. L. Dubois-Rande, and A. Castaigne Myocardial Adrenergic Dysinnervation in Dilated Cardiomyopathy: Cornerstone or Epiphenomenon? J. Nucl. Med., April 1, 2002; 43(4): 536 - 539. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Foody, M. H. Farrell, and H. M. Krumholz {beta}-Blocker Therapy in Heart Failure: Scientific Review JAMA, February 20, 2002; 287(7): 883 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Farrell, J. M. Foody, and H. M. Krumholz {beta}-Blockers in Heart Failure: Clinical Applications JAMA, February 20, 2002; 287(7): 890 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chatterjee Refractory heart failure--drugs and devices Eur. Heart J., December 2, 2001; 22(24): 2227 - 2230. [PDF]
|
|
|
|
 |
|
 Beta-Blockers for CHF: An Updated Meta-Analysis Journal Watch Cardiology, June 1, 2001; 2001(601): 5 - 5. [Full Text]
|
|
|
|
|
|
E. Braunwald Expanding Indications for Beta-Blockers in Heart Failure N. Engl. J. Med., May 31, 2001; 344(22): 1711 - 1712. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
